AI-powered search

Can Risk for Skin Cancer Be Predicted in Solid Organ Transplant Recipients?

SUNTRAC risk assessment calculator predicted incidence of skin cancer with predicted and observed incidence of 6.2 and 7.0 percent, respectively

By Dermsquared Editorial Team | November 23, 2022

The Skin and UV Neoplasia Transplant Risk Assessment Calculator (SUNTRAC) is valid for assessing the risk for skin cancer among solid organ transplant recipients (SOTRs), according to a study published online Nov. 23 in JAMA Dermatology.

Álvaro Gómez-Tomás, M.D., from Hospital Universitari Vall d'Hebron in Barcelona, Spain, and colleagues conducted a retrospective external validation study using data from European SOTRs from transplant centers in the Netherlands and Spain to validate the SUNTRAC tool. The discriminative ability of the SUNTRAC tool was examined and calibration was assessed by comparing projected skin cancer incidences.

"Having a tool that can quickly and correctly stratify SOTRs according to their relative skin cancer risk is a great aid for the clinician and a fundamental step in defining guidelines to ensure adequate screening and dermatological follow-up of these patients," the authors write.

Two authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)


The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us


Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved